Unichem Laboratories Ltd
UNICHEMLABUnichem Laboratories Ltd
UNICHEMLAB
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -104.57 | 2.68 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.27 | 6.55 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Unichem Laboratories Limited is a pharmaceutical company that manufactures active pharmaceutical ingredients (APIs or bulk actives).
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,351.39 | 882.81 | 3,553.47 | 1,280.29 | 1,195.84 | 1,285.33 | 1,317.34 | 1,381.54 | 1,804.50 | 1,822.97 | ||||||||||
Raw Materials | 476.53 | 262.42 | 387.73 | 477.13 | 422.92 | 467.52 | 457.36 | 533.73 | 743.72 | 1,738.04 | ||||||||||
| Power & Fuel Cost | 38.25 | 41.62 | 49.23 | 76.39 | 73.02 | 68.89 | 78.05 | 102.84 | 107.14 | |||||||||||
| Employee Cost | 255.92 | 169.04 | 200.64 | 238.52 | 273.28 | 306.97 | 330.49 | 356.41 | 393.06 | |||||||||||
| Selling & Administrative Expenses | 380.90 | 233.92 | 291.18 | 420.94 | 345.54 | 316.35 | 287.13 | 299.84 | 361.41 | |||||||||||
| Operating & Other expenses | 20.69 | 32.10 | 17.93 | 50.56 | 39.77 | -15.36 | 45.07 | 134.33 | 124.94 | |||||||||||
EBITDA | 179.10 | 143.71 | 2,606.76 | 16.75 | 41.31 | 140.96 | 119.24 | -45.61 | 74.23 | 84.93 | ||||||||||
| Depreciation/Amortization | 38.79 | 43.52 | 50.51 | 67.37 | 81.67 | 84.36 | 91.17 | 113.44 | 113.24 | 112.80 | ||||||||||
| PBIT | 140.31 | 100.19 | 2,556.25 | -50.62 | -40.36 | 56.60 | 28.07 | -159.05 | -39.01 | -27.87 | ||||||||||
| Interest & Other Items | 2.90 | 3.36 | 8.01 | 7.52 | 7.85 | 5.12 | 6.11 | 17.31 | 22.66 | 20.93 | ||||||||||
| PBT | 137.41 | 96.83 | 2,548.24 | -58.14 | -48.21 | 51.48 | 21.96 | -176.36 | -61.67 | -48.80 | ||||||||||
| Taxes & Other Items | 29.30 | -11.85 | 3.34 | -34.35 | 11.97 | 17.15 | -11.09 | 25.86 | 8.80 | 11.77 | ||||||||||
| Net Income | 108.11 | 108.68 | 2,544.90 | -23.79 | -60.18 | 34.33 | 33.05 | -202.22 | -70.47 | -60.57 | ||||||||||
| EPS | 11.91 | 11.96 | 315.72 | -3.38 | -8.55 | 4.88 | 4.69 | -28.72 | -10.01 | -8.60 | ||||||||||
| DPS | 2.00 | 3.00 | 5.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.17 | 0.25 | 0.02 | — | — | 0.82 | 0.85 | — | 0.00 | 0.00 |
Company Updates
Investor Presentation
Investor Presentation
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Unichem Laboratories Ltd | -89.88 | 2.68 | — |
| Sun Pharmaceutical Industries Ltd | 45.34 | 6.47 | 0.75% |
| Cipla Ltd | 31.21 | 4.80 | 0.82% |
| Torrent Pharmaceuticals Ltd | 65.38 | 15.80 | 0.88% |
Price Comparison
Compare UNICHEMLAB with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Unichem Laboratories Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
HDFC Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 5.8571% | Percentage of the fund’s portfolio invested in the stock 1.06% | Change in the portfolio weight of the stock over the last 3 months 0.14% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 23/92 (+1) |
DSP Healthcare Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.7872% | Percentage of the fund’s portfolio invested in the stock 1.56% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 20/33 (-2) |
Franklin India Opportunities Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.5838% | Percentage of the fund’s portfolio invested in the stock 0.64% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 66/72 (-10) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateAug 1, 2022
Dividend/Share
₹4.00
Ex DateEx Date
Aug 1, 2022
Cash Dividend
Ex DateEx DateJul 22, 2021
Dividend/Share
₹4.00
Ex DateEx Date
Jul 22, 2021
Cash Dividend
Ex DateEx DateAug 20, 2020
Dividend/Share
₹4.00
Ex DateEx Date
Aug 20, 2020
Cash Dividend
Ex DateEx DateJul 18, 2019
Dividend/Share
₹4.00
Ex DateEx Date
Jul 18, 2019
Cash Dividend
Ex DateEx DateJul 19, 2018
Dividend/Share
₹5.00
Ex DateEx Date
Jul 19, 2018
Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live
Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 30 September 2024.Powered by Capital Market - Live
The Board of Unichem Laboratories will meet on 30 September 2024 to consider and approve integration and consolidation of the generics formulations business in the US market of M/s. Bayshore Pharmaceuticals LLC (wholly owned subsidiary of Company's holding company, Ipca Laboratories) into Unichem Pharmaceuticals (USA) Inc. (company's wholly owned subsidiary) so as to consolidate all the Ipca Group's USA generics formulations business under one entity.Powered by Capital Market - Live
In an exchange filing made before market hours today, the company said that its board will consider integration and consolidation of the generics formulations business in the US market of Bayshore Pharmaceuticals LLC into Unichem Pharmaceuticals (USA) Inc. so as to consolidate all the Ipca Group's USA generics formulations business under one entity. Bayshore Pharmaceuticals LLC is a wholly owned subsidiary of Unichem's holding company Ipca Laboratories. Unichem Pharmaceuticals (USA) Inc. is the wholly owned subsidiary of Unichem Labs. Unichem Laboratories is a pharmaceutical company. It addresses the needs of therapeutic areas like gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterials, anti-infectives and pain management. The company had reported a consolidated net profit of Rs 9.26 crore in the quarter ended June 2024 as against net loss of Rs 0.67 crore during the previous quarter ended June 2023. Sales rose 5.49% to Rs 446.43 crore in Q1 FY25 over Q1 FY24. Powered by Capital Market - Live
The Board of Unichem Laboratories at its meeting held on 08 August 2024 has approved appointment of Sanjay Jain as the Chief Financial Officer and Key Managerial Personnel of the Company with effect from 8 August 2024. Powered by Capital Market - Live
Net profit of Unichem Laboratories reported to Rs 9.26 crore in the quarter ended June 2024 as against net loss of Rs 0.67 crore during the previous quarter ended June 2023. Sales rose 5.49% to Rs 446.43 crore in the quarter ended June 2024 as against Rs 423.19 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales446.43423.19 5 OPM %9.746.62 - PBDT43.3330.89 40 PBT15.002.12 608 NP9.26-0.67 LP Powered by Capital Market - Live
Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 8 August 2024.Powered by Capital Market - Live
EU Court upholds Rs 126 cr fine imposed on Ipca Labs’ unit; stock jumps 4%
Stocks to watch today: July 28, 2023
CCI approves Ipca Laboratories 59.38% stake buy deal in Unichem Laboratories
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 7.1%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.58% to 0.48%